MINERALYS THERAPEUTICS INC (MLYS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:MLYS • US6031701013

29.77 USD
+1.56 (+5.53%)
At close: Feb 6, 2026
30.58 USD
+0.81 (+2.72%)
After Hours: 2/6/2026, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MLYS. MLYS was compared to 524 industry peers in the Biotechnology industry. While MLYS has a great health rating, there are worries on its profitability. MLYS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • MLYS had negative earnings in the past year.
  • MLYS had a negative operating cash flow in the past year.
  • MLYS had negative earnings in each of the past 5 years.
  • In the past 5 years MLYS always reported negative operating cash flow.
MLYS Yearly Net Income VS EBIT VS OCF VS FCFMLYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • MLYS has a Return On Assets of -28.56%. This is in the better half of the industry: MLYS outperforms 68.51% of its industry peers.
  • MLYS's Return On Equity of -29.73% is fine compared to the rest of the industry. MLYS outperforms 76.34% of its industry peers.
Industry RankSector Rank
ROA -28.56%
ROE -29.73%
ROIC N/A
ROA(3y)-46.99%
ROA(5y)-109.19%
ROE(3y)-50.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MLYS Yearly ROA, ROE, ROICMLYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MLYS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLYS Yearly Profit, Operating, Gross MarginsMLYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, MLYS has more shares outstanding
  • MLYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MLYS Yearly Shares OutstandingMLYS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
MLYS Yearly Total Debt VS Total AssetsMLYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 56.10 indicates that MLYS is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of MLYS (56.10) is better than 97.14% of its industry peers.
  • MLYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 56.1
ROIC/WACCN/A
WACCN/A
MLYS Yearly LT Debt VS Equity VS FCFMLYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 25.50 indicates that MLYS has no problem at all paying its short term obligations.
  • MLYS's Current ratio of 25.50 is amongst the best of the industry. MLYS outperforms 97.33% of its industry peers.
  • MLYS has a Quick Ratio of 25.50. This indicates that MLYS is financially healthy and has no problem in meeting its short term obligations.
  • MLYS's Quick ratio of 25.50 is amongst the best of the industry. MLYS outperforms 97.33% of its industry peers.
Industry RankSector Rank
Current Ratio 25.5
Quick Ratio 25.5
MLYS Yearly Current Assets VS Current LiabilitesMLYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • MLYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.79%, which is quite good.
EPS 1Y (TTM)9.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.13% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.55%
EPS Next 2Y17.28%
EPS Next 3Y7.95%
EPS Next 5Y22.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLYS Yearly Revenue VS EstimatesMLYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
MLYS Yearly EPS VS EstimatesMLYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MLYS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLYS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLYS Price Earnings VS Forward Price EarningsMLYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLYS Per share dataMLYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.28%
EPS Next 3Y7.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MLYS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MINERALYS THERAPEUTICS INC

NASDAQ:MLYS (2/6/2026, 8:00:01 PM)

After market: 30.58 +0.81 (+2.72%)

29.77

+1.56 (+5.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)02-10
Inst Owners103.11%
Inst Owner Change1.72%
Ins Owners1.5%
Ins Owner Change-7.43%
Market Cap2.36B
Revenue(TTM)N/A
Net Income(TTM)-171.36M
Analysts84
Price Target51.13 (71.75%)
Short Float %14.08%
Short Ratio7.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.95%
Min EPS beat(2)10.13%
Max EPS beat(2)17.77%
EPS beat(4)4
Avg EPS beat(4)14.96%
Min EPS beat(4)10.13%
Max EPS beat(4)21.13%
EPS beat(8)5
Avg EPS beat(8)4.45%
EPS beat(12)9
Avg EPS beat(12)13.71%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.01%
PT rev (3m)14.57%
EPS NQ rev (1m)6.98%
EPS NQ rev (3m)16.18%
EPS NY rev (1m)1.26%
EPS NY rev (3m)9.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.09
P/tB 4.09
EV/EBITDA N/A
EPS(TTM)-2.95
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-2.17
FCFYN/A
OCF(TTM)-2.17
OCFYN/A
SpS0
BVpS7.28
TBVpS7.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.56%
ROE -29.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.99%
ROA(5y)-109.19%
ROE(3y)-50.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.5
Quick Ratio 25.5
Altman-Z 56.1
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.98%
EPS Next Y30.55%
EPS Next 2Y17.28%
EPS Next 3Y7.95%
EPS Next 5Y22.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.43%
EBIT Next 3Y0.05%
EBIT Next 5Y23.54%
FCF growth 1Y-174.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-174.73%
OCF growth 3YN/A
OCF growth 5YN/A

MINERALYS THERAPEUTICS INC / MLYS FAQ

Can you provide the ChartMill fundamental rating for MINERALYS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to MLYS.


What is the valuation status of MINERALYS THERAPEUTICS INC (MLYS) stock?

ChartMill assigns a valuation rating of 0 / 10 to MINERALYS THERAPEUTICS INC (MLYS). This can be considered as Overvalued.


Can you provide the profitability details for MINERALYS THERAPEUTICS INC?

MINERALYS THERAPEUTICS INC (MLYS) has a profitability rating of 1 / 10.


How financially healthy is MINERALYS THERAPEUTICS INC?

The financial health rating of MINERALYS THERAPEUTICS INC (MLYS) is 8 / 10.


What is the earnings growth outlook for MINERALYS THERAPEUTICS INC?

The Earnings per Share (EPS) of MINERALYS THERAPEUTICS INC (MLYS) is expected to grow by 30.55% in the next year.